/stocks — the workspaceLOADING
Johnson & Johnson develops prescription drugs, including the cancer therapy Darzalex and immunology drugs Stelara and Tremfya, and sells surgical tools, orthopedic implants, and vision products through its MedTech arm. Consumer brands like Tylenol left with the 2023 Kenvue spinoff.
JOHNSON & JOHNSON (JNJ) is a pharmaceutical preparations company. Piotroski F-Score 3/8. 16 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-07-15 from JNJ's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Led by Joaquin Duato · see pay & career →
Johnson & Johnson has raised its dividend for more than 60 consecutive years — a “Dividend King” that has increased its payout through every recession since the 1960s.
Source: Company filings · More →
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
eight-variable model; a screen for earnings-quality review, not an accusation
A plain-English read on JNJ plus an auto-SWOT — built from JNJ's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate JNJ using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Lloyd DoggettU.S. Representative · TX-35 | BUY | $1,001 - $15,000 | filed 2026-07-06 |
| Rohit KhannaU.S. Representative · CA-17 | SELL | $1,001 - $15,000 | filed 2026-06-09 |
| Company | Stake value | % of company owned |
|---|---|---|
| Protagonist Therapeutics Inc.PTGX | $258.1M | 3.8% |
| Nanobiotix S.A.NBTX | $173.6M | 11.6% |
| MeiraGTx Holdings plcMGTX | $57.5M | 7.2% |
| Rapport Therapeutics, Inc.RAPP | $55.8M | 3.7% |
| CVRx, Inc.CVRX | $38.1M | 15.2% |
| Contineum Therapeutics Inc.CTNM | $25.8M | 8.6% |
| Legend Biotech Corporation | $14.7M | — |
| Xencor, Inc.XNCR | $9.0M | 1.0% |
| Procept BioRobotics Corporation | $9.0M | — |
| Fate Therapeutics, Inc.FATE | $4.1M | 2.9% |
| Neumora Therapeutics, Inc.NMRA | $3.6M | 1.00% |
| Rallybio Corporation | $1.4M | — |
| Vor Biopharma, Inc.VOR | $959K | 0.10% |
| Standard BioTools, Inc.LAB | $287K | 0.08% |
| Nano-X Imaging Ltd.NNOX | $190K | 0.12% |
Long US equity positions from JNJ's own 13F-HR (SEC), reported quarterly and lagged up to 45 days. “% of company owned” = reported shares ÷ that company's latest shares outstanding.
| Wengel Kathryn EEVP, Chief TO and Risk Officer | SELL | $2.4M | view → |
| Decker Robert JVP Corporate Controller | SELL | $1.0M | view → |
| Schmid TimothyEVP, WW Chair, MedTech | SELL | $325K | view → |
| Swanson James D.EVP, CIO | SELL | $15.1M | view → |
Projected from JNJ's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment JNJ files its announcement.
JNJ has rallied after 6 of its last 8 earnings reports.
Earnings reactions have been mild.
JNJ has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+5.0% and -1.0%).
A more typical earnings reaction has been approximately ±0.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-14 | +0.3% |
| 2026-01-21 | +0.1% |
| 2025-10-14 | +0.1% |
| 2025-07-16 | +5.0% |
| 2025-04-15 | -0.3% |
| 2025-01-22 | -1.0% |
| 2024-10-15 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +1.7% |
| 2024-07-17 | +2.9% |